Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Sevimli Dikicier B, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H.
Soegiharto R, et al. Among authors: matsuo y.
JAMA Dermatol. 2024 Sep 1;160(9):927-935. doi: 10.1001/jamadermatol.2024.2056.
JAMA Dermatol. 2024.
PMID: 39018068